本文關(guān)鍵詞： 細(xì)胞 周期 蛋白 依賴 激酶 抑制 因子 誘導(dǎo)型 多能 干細(xì)胞 形成 作用　出處：《南京大學(xué)》2010年博士論文　論文類型：學(xué)位論文

【摘要】：干細(xì)胞研究作為一項(xiàng)新興的學(xué)科,憑借其全新的生物學(xué)概念和良好的臨床應(yīng)用前景,正在受到越來越大的關(guān)注。干細(xì)胞從來源上可分為胚胎干細(xì)胞和成體干細(xì)胞兩種。胚胎干細(xì)胞是從處于囊胚期的胚胎的內(nèi)細(xì)胞層分離出來后,在體外培養(yǎng)傳代形成的干細(xì)胞。它具有快速增殖的特性,并能夠分化成三個(gè)胚層的細(xì)胞和形成個(gè)體。這種能力被認(rèn)為是胚胎干細(xì)胞特有的多向分化潛能。成體干細(xì)胞則來自成熟個(gè)體的各個(gè)器官,為所在的器官提供特定的細(xì)胞類型以維持該器官的功能。由于獲取胚胎干細(xì)胞存在倫理學(xué)問題(需要摧毀胚胎)和成體干細(xì)胞在單個(gè)器官中的數(shù)量極其稀少、收集上存在難度,這兩種干細(xì)胞在臨床的治療前景并不十分樂觀。目前對(duì)這兩種干細(xì)胞的研究更多的是對(duì)其干細(xì)胞生物學(xué)特性的研究。由于上述的問題和生物學(xué)技術(shù)的進(jìn)步,一種“人工”干細(xì)胞的概念正逐步興起。和天然的干細(xì)胞不同,“人工”干細(xì)胞可以從機(jī)體的任何細(xì)胞中“制作”出來,而“加工”出的細(xì)胞能獲得和胚胎干細(xì)胞相似的多向分化潛能和自我更新的能力。目前有三種方法可以制作“人工”干細(xì)胞。最早提出的方法是通過核移植將未受精的卵細(xì)胞的細(xì)胞核替換成成熟的體細(xì)胞的細(xì)胞核,利用卵細(xì)胞內(nèi)特有的細(xì)胞微環(huán)境來改變植入的體細(xì)胞胞核的基因表達(dá),從而將該細(xì)胞核轉(zhuǎn)變?yōu)榕咛ジ杉?xì)胞的細(xì)胞核。通過該方法獲得的干細(xì)胞在基因表達(dá)、DNA甲基化程度方面、多向分化潛能和自我更新能力和同樣來源的胚胎干細(xì)胞極為接近。因此,從這一點(diǎn)看,它最能替代胚胎干細(xì)胞。然而,由于它需要熟練的核移植技術(shù)、昂貴的設(shè)備和捐獻(xiàn)卵子,這種方法在人類細(xì)胞上始終未能實(shí)現(xiàn)。另一種方法和核移植的方法類似,它是通過核融合的方法,將一個(gè)胚胎干細(xì)胞和一個(gè)體細(xì)胞相融合,利用胚胎干細(xì)胞內(nèi)的特定微環(huán)境改變體細(xì)胞核的基因表達(dá)狀態(tài)。這個(gè)方法存在的缺點(diǎn)是最終得到的細(xì)胞為4倍體的細(xì)胞,因此這種細(xì)胞上也無法在人體上應(yīng)用。最后一種方法,是用病毒作為載體向已經(jīng)分化成熟的體細(xì)胞內(nèi)導(dǎo)入特定的4個(gè)轉(zhuǎn)錄因子(Oct4, Sox2, Klf4和c-Myc.),以此來改變體細(xì)胞的基因表達(dá)狀態(tài)。被導(dǎo)入的細(xì)胞在4個(gè)轉(zhuǎn)錄因子的作用下,其基因的表達(dá)將返回胚胎干細(xì)胞的狀態(tài),進(jìn)而再次獲得胚胎干細(xì)胞特有的多向分化潛能。通過這種方法制作的干細(xì)胞被稱為誘導(dǎo)型多能干細(xì)胞(induced pluripotent stem cells, iPSCs)。這種方法由于簡單、經(jīng)濟(jì),并能使用病人的皮膚細(xì)胞直接制作,具有極好的臨床應(yīng)用前景。目前利用這種方法來誘導(dǎo)多能干細(xì)胞存在誘導(dǎo)效率低、具體分子機(jī)制不明等問題。其中,阻礙誘導(dǎo)型多能干細(xì)胞形成的已知的分子機(jī)制之一是抗癌基因p53激活后的細(xì)胞周期抑制和細(xì)胞凋亡�？紤]到為臨床服務(wù)的需要,克服誘導(dǎo)效率低的缺點(diǎn)是當(dāng)前研究的主要方向之一。本研究首先考察了使用病毒做載體制作誘導(dǎo)型多能干細(xì)胞的可行性,并驗(yàn)證了所誘導(dǎo)出的細(xì)胞具有胚胎干細(xì)胞特性。然后,從細(xì)胞周期的調(diào)節(jié)通路入手,探索其他細(xì)胞周期調(diào)節(jié)因子在誘導(dǎo)性多能干細(xì)胞形成過程中的作用。第一部分誘導(dǎo)型多能干細(xì)胞的制作研究背景：通過向分化成熟的體細(xì)胞導(dǎo)入4個(gè)轉(zhuǎn)錄因子(Oct4、Sox2、Klf4和c-Myc)可誘導(dǎo)出具有多向分化潛能的干細(xì)胞。這種誘導(dǎo)型多能干細(xì)胞與其他“人工”干細(xì)胞的技術(shù)相比,有簡單、高效、能直接使用病人皮膚細(xì)胞制作的特點(diǎn),具有良好的科研和臨床應(yīng)用前景。實(shí)驗(yàn)?zāi)康模簩?shí)踐誘導(dǎo)多能干細(xì)胞的技術(shù),即在分化成熟的細(xì)胞中誘導(dǎo)出多向分化潛能的干細(xì)胞,并考察其在誘導(dǎo)后獲得的多向分化潛能。實(shí)驗(yàn)方法：使用感受態(tài)細(xì)菌制備含有四個(gè)轉(zhuǎn)錄因子編碼區(qū)的質(zhì)粒(Oct4、Sox2、Klf4和c-Myc)。原代分離、擴(kuò)增小鼠胚胎成纖維細(xì)胞,并把它作為誘導(dǎo)的靶細(xì)胞。通過逆轉(zhuǎn)錄病毒導(dǎo)入基因的方法轉(zhuǎn)導(dǎo)小鼠胚胎成纖維細(xì)胞,將其誘導(dǎo)成誘導(dǎo)型多能干細(xì)胞。在多能干細(xì)胞成功誘導(dǎo)后,挑取單個(gè)細(xì)胞集落并擴(kuò)增、培育形成獨(dú)立細(xì)胞系。通過多種方法考察所形成的誘導(dǎo)型多能干細(xì)胞系的多向分化潛能,包括胚胎干細(xì)胞的標(biāo)識(shí)物的表達(dá)、畸胎瘤的形成能力和嵌合體形成的能力。實(shí)驗(yàn)結(jié)果：小鼠胚胎成纖維細(xì)胞經(jīng)過14天的誘導(dǎo)后逐步獲得了與胚胎干細(xì)胞相似的細(xì)胞集落形態(tài)。這些集落在形成獨(dú)立細(xì)胞系以后,表達(dá)有胚胎干細(xì)胞特有的標(biāo)記物Oct4、Sox2、Nanog和SSEA-1。這些誘導(dǎo)型多能干細(xì)胞在皮下注射入NOD/SCID免疫缺陷小鼠后,能形成畸胎瘤。將畸胎瘤進(jìn)行常規(guī)病理染色后發(fā)現(xiàn),畸胎瘤組織含有包括有外胚層、中胚層和內(nèi)胚層在內(nèi)的多種細(xì)胞類型。將這些誘導(dǎo)型多能干細(xì)胞植入胚胎后,該胚胎能形成健康個(gè)體。在這些個(gè)體身上,發(fā)現(xiàn)有由植入的誘導(dǎo)型多能干細(xì)胞來源的毛發(fā)。實(shí)驗(yàn)小結(jié)：使用分化成熟的小鼠胚胎成纖維細(xì)胞可以誘導(dǎo)出具有多向分化潛能的干細(xì)胞。通過這個(gè)方法誘導(dǎo)出的多能干細(xì)胞具有和胚胎干細(xì)胞類似的形態(tài)、標(biāo)識(shí)物表達(dá)、向多胚層細(xì)胞分化的能力以及參與正常機(jī)體發(fā)育的能力。第二部分細(xì)胞周期蛋白依賴激酶抑制因子對(duì)誘導(dǎo)型多能干細(xì)胞的形成抑制作用研究背景：雖然在成熟的體細(xì)胞誘導(dǎo)多能干細(xì)胞有很好的臨床應(yīng)用前景,但是其誘導(dǎo)效率低的特點(diǎn)阻礙了它在臨床上的應(yīng)用。在誘導(dǎo)型多能干細(xì)胞形成的過程中,起阻礙作用的途經(jīng)之一是由抗癌基因p53控制下的細(xì)胞周期抑制和細(xì)胞凋亡。而前者是通過上調(diào)細(xì)胞周期蛋白依賴激酶抑制因子p21來完成。細(xì)胞周期蛋白依賴激酶抑制因子為一多成員的抑制分子家族,包括有p16、p18、p19和p21、p27等因子,其中p18和p27在造血干細(xì)胞的作用是抑制其細(xì)胞周期和自我更新。我們?cè)O(shè)想p18和p27在iPSCs誘導(dǎo)過程中可能也會(huì)起一定作用。實(shí)驗(yàn)?zāi)康模貉芯亢蚿21同屬一類的細(xì)胞周期抑制因子：p18和p27在誘導(dǎo)型多能干細(xì)胞形成過程中所起的作用。實(shí)驗(yàn)方法：測(cè)定小鼠胚胎成纖維細(xì)胞和小鼠胚胎干細(xì)胞細(xì)胞周期的差別。使用SSEA-1這一胚胎干細(xì)胞的標(biāo)識(shí)物標(biāo)識(shí)在多能干細(xì)胞誘導(dǎo)過程中的被成功誘導(dǎo)的細(xì)胞,觀察其細(xì)胞周期的變化。測(cè)定p18和p27在小鼠胚胎成纖維細(xì)胞、小鼠胚胎干細(xì)胞和誘導(dǎo)型多能干細(xì)胞中mRNA的表達(dá)和在誘導(dǎo)型多能干細(xì)胞形成過程中的表達(dá)水平。使用取材白p18或p27基因敲除小鼠的胚胎成纖維細(xì)胞制作誘導(dǎo)型多能干細(xì)胞,觀察野生型、雜合體和純合體的小鼠胚胎成纖維細(xì)胞在誘導(dǎo)成多能干細(xì)胞時(shí)誘導(dǎo)效率的不同。制作含p18或p27編碼區(qū)的質(zhì)粒。使用由該質(zhì)粒制作的逆轉(zhuǎn)錄病毒分別感染p18缺陷型或p27缺陷型的小鼠胚胎成纖維細(xì)胞,觀察在p18或p27在相應(yīng)的基因缺陷型的細(xì)胞重新表達(dá)后它們對(duì)多能干細(xì)胞的誘導(dǎo)效率的影響。使用藥物Roscovitine和PD-0332991分別直接抑制p27的靶分子CDK2或p18的靶分子CDK4/6,來觀察誘導(dǎo)型多能干細(xì)胞形成時(shí)的誘導(dǎo)效率。實(shí)驗(yàn)結(jié)果：分化成熟的小鼠胚胎成纖維細(xì)胞的細(xì)胞周期周轉(zhuǎn)緩慢,而胚胎干細(xì)胞的細(xì)胞周期活躍。在誘導(dǎo)型多能干細(xì)胞形成的過程中,被成功誘導(dǎo)的細(xì)胞逐步獲得活躍的細(xì)胞周期特性。與之相應(yīng)的是,細(xì)胞周期抑制因子p18和p27在小鼠胚胎成纖維細(xì)胞的mRNA表達(dá)量大于其在誘導(dǎo)型多能干細(xì)胞和胚胎干細(xì)胞的表達(dá)量。p18和p27的mRNA在多能干細(xì)胞誘導(dǎo)的過程中其表達(dá)量低于對(duì)照組。在把p18或p27的基因敲除后,小鼠胚胎成纖維細(xì)胞形成多能干細(xì)胞的誘導(dǎo)成功效率上升10倍以上,且該效率的提升有基因劑量依賴性。將p18或p27基因重新導(dǎo)入相應(yīng)的基因缺陷型細(xì)胞后,其對(duì)誘導(dǎo)型多能干細(xì)胞形成的抑制作用可恢復(fù)。通過藥物直接抑制p18或p27的靶分子,可模擬p18或p27對(duì)誘導(dǎo)型多能干細(xì)胞形成的抑制作用,提示p18或p27對(duì)誘導(dǎo)型多能干細(xì)胞形成的抑制作用是分別通過抑制其靶分子CDK4/6或CDK2、進(jìn)而抑制所誘導(dǎo)細(xì)胞的細(xì)胞周期來實(shí)現(xiàn)的。實(shí)驗(yàn)結(jié)論：在體細(xì)胞內(nèi)表達(dá)的p18和p27參與了對(duì)誘導(dǎo)型多能干細(xì)胞形成的抑制。這種抑制作用具有基因劑量依賴性。這種抑制作用分別是通過抑制靶分子CDK4/6或CDK2、進(jìn)而抑制細(xì)胞周期來實(shí)現(xiàn)的。
[Abstract]:Stem cell research as a new subject, with its new concept of biology and good clinical application prospect, is getting more and more attention. Stem cells from the source can be divided into embryonic stem cells and adult stem cells. Two kinds of embryonic stem cells from the blastocyst stage embryos in the inner cell layer after separated, in the passage formed by stem cells cultured in vitro. It has the characteristics of rapid proliferation, and can differentiate into three germ cells and the formation of the individual. This ability is thought to be multipotent embryonic stem cell specific. Adult stem cells from various organs of mature individuals, specific cell types in order to maintain the function of organs for the organs. Due to the existence of embryonic stem cells (ethical issues need to destroy the embryo) and adult stem cells in a single organ in the number of extremely rare, are difficult to collect Of these two types of stem cells in clinical treatment in the future is not very optimistic. The current of the two kinds of stem cell research is more on the biological characteristics of stem cell research. Because of the above problems and the development of biological technology, an "artificial" stem cell concept is gradually rising and different natural. The stem cells, "artificial" stem cells from any cell in the body in the "production", and "processing" of the cell can be obtained and the ability of embryonic stem cell differentiation and self-renewal similar. At present, there are three ways to make "people" stem cells. The earliest methods proposed is not fertilized by nuclear transfer of the nucleus of an egg cell replacement into mature somatic cell nuclei, micro environment to change into somatic cell nucleus gene expression using the characteristic of eggs within the cells, and the nuclear transformation As an embryonic stem cell obtained by this method. The expression of stem cell gene, DNA methylation, multilineage differentiation potential and self-renewal ability and also the source of embryonic stem cells is very close. Therefore, from this point of view, it can replace embryonic stem cells. However, since it requires nuclear transplantation skilled, expensive equipment and the method of egg donation, not always in human cells. Another method and nuclear transplantation is similar, it is through the method of nuclear fusion, an embryonic stem cell and somatic cell fusion, using embryonic stem cells in specific microenvironment changes in somatic cell nuclear gene expression. This method has the disadvantages of the resulting cells is 4 times of body cells, so the cells can not in human applications. Finally a method is used as the carrier to have virus The 4 transcription factors differentiated somatic cells into specific (Oct4, Sox2, Klf4 and c-Myc.), in order to change the expression of somatic cell gene was introduced into the cell. In 4 transcription factors under the action of the gene will return the embryonic stem cell state, and again won the multi the differentiation potential of embryonic stem cell specific production. The stem cell known as induced pluripotent stem cells by this method (induced pluripotent stem cells, iPSCs). Since this method is simple, economic, and can use the patient's skin cells directly, has excellent clinical application prospect. At present the method of induced pluripotent stem cells induced by low efficiency, specific molecular mechanism is unknown. Among them, one of the molecular mechanisms of block induced pluripotent stem cell formation is known to the cell cycle of tumor suppressor gene p53 after activation and inhibition Cell apoptosis. Taking into account the need to provide clinical services, to overcome the disadvantage of low efficiency of induction is one of the main direction of current research. This study first investigated the carrier making induced pluripotent stem cells, the feasibility of using the virus, it is verified that the induced cells with embryonic stem cell like properties. Then, starting from the cell cycle. Pathways to explore other cell cycle regulatory factors in the pathogenesis of induced pluripotent stem cells. The first part of induced pluripotent stem cells, making the research background: through to the differentiation and maturation of somatic cells into 4 transcription factors (Oct4, Sox2, Klf4 and c-Myc) can induce pluripotent stem this kind of cells. Induced pluripotent stem cells and other "artificial" stem cell technology compared to a simple, efficient and can be used directly with characteristics of skin cell production, has the good scientific research and Clinical application. Objective: the practice of induced pluripotent stem cells, which induce multipotential stem cells in differentiation of mature cells, and investigate its in induced differentiation potential. Methods: using the competent bacteria preparation containing four transcription factor encoding plasmid (Oct4 Sox2, Klf4, and c-Myc). Primary isolation, amplification of mouse embryonic fibroblasts, and take it as the target cell induced by retroviral gene transfection method. The transduction of mouse embryonic fibroblast cells, the induction of inducible pluripotent stem cells. After induction of pluripotent stem cells, from single cells colony and amplification, foster the formation of independent cell lines. Multipotential differentiation induced pluripotent stem cell lines formed by a variety of methods to investigate, including the expression of embryonic stem cell marker, teratoma formation ability And the chimera formation ability. Results: mouse embryonic fibroblast cells after 14 days of induction after gradually obtained with embryonic stem cell similar colony morphology. The colony after the formation of independent cell lines, the expression of embryonic stem cell specific markers Oct4, Sox2, Nanog and SSEA-1. of the inducible pluripotent stem cells in immunodeficient mice after subcutaneous injection into NOD/SCID, can form teratomas. The teratoma were routine pathological staining found, teratoma tissue contains including ectoderm, mesoderm and endoderm, a variety of cell types. These induced pluripotent stem cells implantation embryo, the embryo can form healthy individuals in these individuals., found by implantation of induced pluripotent stem cells. Conclusion: the use of hair the mature differentiation of mouse embryonic fibroblasts can induce to produce more The differentiation potential of stem cells. By this method the induced pluripotent stem cells and embryonic stem cells have similar morphology and marker expression, ability to mesoderm cell differentiation and ability to participate in normal body development. The second part of the cyclin dependent kinase inhibitor due to the formation of induced pluripotent stem cells, inhibition of background: Although in the mature cell induced pluripotent stem cells have good prospects for clinical application, but its low inducing efficiency hinders its clinical application. The induced pluripotent stem cell formation process, one of the obstacles is passing by the cell cycle inhibitory and apoptosis gene under the control of p53. While the former is through upregulation of cyclin dependent kinase inhibitor p21. Cyclin dependent kinase inhibitor is a member of the tumor For molecules, including p16, P18, P19 and p21, p27 and other factors, including P18 and p27 in hematopoietic stem cells inhibits the cell cycle and self-renewal. We assume that P18 and p27 during iPSCs induction may also play a role. Objective: To study p21 and belong to the same class cell cycle inhibitor: P18 and p27 in induced pluripotent stem cells, which will play a role in the process of experiment. Methods: Determination of fibroblast and mouse embryonic stem cell cycle differences. The application of SSEA-1 in the embryonic mouse embryonic stem cell marker identification in induced pluripotent stem cell process was successfully induced cells, observe the change of cell cycle. The determination of P18 in mouse embryonic fibroblasts and p27 mouse embryonic stem cells and induced pluripotent stem cells and the expression of mRNA in induced pluripotent stem cells formed in the process of expression The level of P18 or p27 were used. The white gene knockout mouse embryonic fibroblasts produced induced pluripotent stem cells was observed in wild-type mouse embryos, heterozygote and homozygote fibroblasts induced pluripotent stem cells induced into efficiency in the different production. Plasmid containing P18 or p27 encoding region of mouse. The use of fiber cells produced by the retrovirus plasmid were infected with P18 defective or defective p27, observed in the P18 or p27 gene defects in the corresponding cell re expression of pluripotent stem cells induced by efficiency. The influence of target molecules of CDK4/6 using the drug Roscovitine and PD-0332991 respectively the direct inhibition of p27 target molecules of CDK2 or P18, to observe the induction efficiency of induced pluripotent stem cells during the formation. Results: the differentiation of mouse embryonic mature into cell cycle and the slow turnover of embryonic stem cells The active cell cycle. In the process of induced pluripotent stem cell formation, was successfully induced cells gradually get cell cycle characteristics of active. Correspondingly, the cell cycle inhibitor of P18 and p27 in mouse embryonic fibroblasts mRNA expression induced pluripotent stem than in the expression of.P18 and p27 cells and embryonic stem cells in mRNA induced pluripotent stem cell in its expression level is lower than the control group. The P18 or p27 gene knockout mouse embryonic fibroblast cells, formation of pluripotent stem cells successfully induced efficiency increases more than 10 times, and the efficiency of gene dose dependent. The P18 or p27 gene deficient cells re import the corresponding after its inhibitory effect on induced pluripotent stem cell formation can be restored. The target molecule drugs through direct inhibition of P18 or p27, can simulate the P18 or p27 on the induction type Inhibition of stem cell formation, suggesting that inhibition of P18 or p27 on induced pluripotent stem cells are formed respectively by inhibiting the target molecules of CDK4/6 or CDK2, and the inhibition of cell cycle induced by the cell to achieve. Conclusion: expression in somatic cells of P18 and p27 were involved in induced pluripotent stem the inhibition of cell formation. This inhibition is dose dependent gene. This inhibition is through inhibition of target molecules of CDK4/6 or CDK2, and inhibit the cell cycle to achieve.

【學(xué)位授予單位】：南京大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2010
【分類號(hào)】：R329.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 ;中美科學(xué)家合作利用人類多能干細(xì)胞分化生成星型膠質(zhì)細(xì)胞[J];生物學(xué)教學(xué);2012年05期

2 陶家祥;干細(xì)胞淺說[J];世界科學(xué);2000年11期

3 何文俊;葉玲玲;陳昭烈;;禽類多能干細(xì)胞的研究與應(yīng)用[J];生物技術(shù)通報(bào);2009年06期

4 李林鳳;關(guān)偉軍;馬月輝;白秀娟;呂春榮;顧恩妍;;獲得多能干細(xì)胞的方法和新進(jìn)展[J];中國獸醫(yī)學(xué)報(bào);2009年11期

5 金穎;;多能干細(xì)胞研究進(jìn)展[J];細(xì)胞生物學(xué)雜志;2009年05期

6 景毅;楊秀霞;;誘導(dǎo)性多能干細(xì)胞的研究概況[J];科技資訊;2010年15期

7 ;體細(xì)胞“變身”多能干細(xì)胞誘導(dǎo)機(jī)制被揭[J];企業(yè)技術(shù)開發(fā);2010年13期

8 ;西班牙科學(xué)家用人頭發(fā)高效培育出誘導(dǎo)性多能干細(xì)胞[J];生物學(xué)教學(xué);2009年04期

9 李紅;多能干細(xì)胞——發(fā)育毒性研究的新思路[J];國外醫(yī)學(xué)(衛(wèi)生學(xué)分冊(cè));2004年03期

10 周一葉;曾凡一;曾溢滔;;逆轉(zhuǎn)生命時(shí)鐘:誘導(dǎo)性多能干細(xì)胞[J];科學(xué);2008年06期

相關(guān)會(huì)議論文 前10條

1 卞合濤;黃衛(wèi);;誘導(dǎo)性多能干細(xì)胞[A];中華醫(yī)學(xué)會(huì)第十三次全國神經(jīng)病學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2010年

2 柯昌能;利天增;徐盈斌;祁少海;黃冰;謝舉臨;;老年人皮膚多能干細(xì)胞的分離及有效擴(kuò)增[A];第八屆全國燒傷外科學(xué)年會(huì)論文匯編[C];2007年

3 邱慧穎;王健民;夏榮;周虹;龔勝藍(lán);高磊;解琳娜;胡曉霞;;小鼠骨髓多能干細(xì)胞體外培養(yǎng)建系及其生物學(xué)特性研究[A];第10屆全國實(shí)驗(yàn)血液學(xué)會(huì)議論文摘要匯編[C];2005年

4 章小清;;多能干細(xì)胞神經(jīng)分化:神經(jīng)系統(tǒng)基礎(chǔ)與應(yīng)用研究的橋梁[A];中國神經(jīng)科學(xué)學(xué)會(huì)第九屆全國學(xué)術(shù)會(huì)議暨第五次會(huì)員代表大會(huì)論文摘要集[C];2011年

5 范力星;冀凱宏;熊俊;胡凱猛;劉厚奇;;骨髓源性多能干細(xì)胞(MMSC)向多巴胺能神經(jīng)元的體外分化[A];中國解剖學(xué)會(huì)第十一屆全國組織學(xué)與胚胎學(xué)青年學(xué)術(shù)研討會(huì)論文匯編[C];2009年

6 趙春華;房柏俊;廖聯(lián)明;史明霞;楊少光;;人胎兒來源Flk1~+CD34~-表型多能干細(xì)胞分離與鑒定(英文)[A];中國微循環(huán)學(xué)會(huì)第五屆中國微循環(huán)學(xué)術(shù)大會(huì)論文摘要匯編[C];2004年

7 林炳亮;高志良;;骨髓干細(xì)胞移植的研究現(xiàn)狀[A];廣東省肝臟病學(xué)會(huì)2007年年會(huì)論文集[C];2007年

8 姚海雷;張文成;王思涵;李保偉;張銳;習(xí)佳飛;周軍年;呂洋;曾泉;施雙雙;何麗娟;南雪;李艷華;岳文;裴雪濤;;誘導(dǎo)臍帶血來源的CD34+細(xì)胞重編程獲得誘導(dǎo)性多能干細(xì)胞(iPS cells)[A];第12屆全國實(shí)驗(yàn)血液學(xué)會(huì)議論文摘要[C];2009年

9 李恩琴;金潤銘;;兒童誘導(dǎo)性多能干細(xì)胞的建立與造血分化[A];中華醫(yī)學(xué)會(huì)第十七次全國兒科學(xué)術(shù)大會(huì)論文匯編（上冊(cè)）[C];2012年

10 劇世強(qiáng);芮榮;;MicroRNA在多能干細(xì)胞的表達(dá)與功能[A];中國畜牧獸醫(yī)學(xué)會(huì)動(dòng)物繁殖學(xué)分會(huì)第十六屆學(xué)術(shù)研討會(huì)論文集[C];2012年

相關(guān)重要報(bào)紙文章 前10條

1 記者 張磊;我國培育出多能干細(xì)胞克隆豬[N];健康報(bào);2013年

2 記者 葉青;體細(xì)胞“變身”機(jī)制明確了[N];廣東科技報(bào);2010年

3 記者 林亞茗　通訊員 韓青海 李潔蔚 朱丹萍;尿液中誘導(dǎo)出多能干細(xì)胞[N];南方日?qǐng)?bào);2011年

4 ;維生素C打開多能干細(xì)胞治病之門[N];南方日?qǐng)?bào);2011年

5 錢洛瀅 記者 王春;乳腺中發(fā)現(xiàn)多能干細(xì)胞[N];科技日?qǐng)?bào);2014年

6 記者 顧鋼;德科學(xué)家找到感應(yīng)多能干細(xì)胞[N];科技日?qǐng)?bào);2009年

7 記者 張建華;糖尿病、地貧癥或?qū)⒃庥隹诵荹N];人民日?qǐng)?bào)海外版;2011年

8 記者 常麗君;美用多能干細(xì)胞培育出胃組織[N];科技日?qǐng)?bào);2014年

9 常麗君;吸脂術(shù)去除的脂肪含新型多能干細(xì)胞[N];科技日?qǐng)?bào);2013年

10 葛進(jìn);日發(fā)現(xiàn)多能干細(xì)胞向外胚葉分化控制基因[N];科技日?qǐng)?bào);2008年

相關(guān)博士學(xué)位論文 前10條

1 潘筱;Oct4翻譯后修飾調(diào)控多能干細(xì)胞自我更新和定向分化的機(jī)理研究[D];浙江大學(xué);2015年

2 平曉春;細(xì)胞周期蛋白依賴激酶抑制因子對(duì)誘導(dǎo)型多能干細(xì)胞形成的抑制作用[D];南京大學(xué);2010年

3 邱慧穎;小鼠骨髓多能干細(xì)胞建系及其造血重建作用的研究[D];第二軍醫(yī)大學(xué);2005年

4 史春夢(mèng);真皮來源成體多能干細(xì)胞的生物學(xué)性狀與促進(jìn)創(chuàng)傷修復(fù)的實(shí)驗(yàn)研究[D];第三軍醫(yī)大學(xué);2004年

5 趙宏喜;克服多能干細(xì)胞移植免疫排斥反應(yīng)的實(shí)驗(yàn)研究[D];第四軍醫(yī)大學(xué);2009年

6 付常皓;人胚胎多能干細(xì)胞的分離鑒定和向軟骨細(xì)胞分化誘導(dǎo)的研究[D];吉林大學(xué);2015年

7 劉麗;小鼠誘導(dǎo)式多能干細(xì)胞向牙源性細(xì)胞分化的實(shí)驗(yàn)研究[D];第四軍醫(yī)大學(xué);2012年

8 張麗飛;人誘導(dǎo)性多能干細(xì)胞人源化培養(yǎng)體系的建立和研究[D];浙江大學(xué);2013年

9 王穎佳;WAS綜合征特異性無整合誘導(dǎo)性多能干細(xì)胞體外造血分化及基因靶向編輯研究[D];浙江大學(xué);2013年

10 李恩琴;兒童急性早幼粒細(xì)胞白血病的臨床及相關(guān)誘導(dǎo)性多能干細(xì)胞研究[D];華中科技大學(xué);2012年

相關(guān)碩士學(xué)位論文 前10條

1 馬海波;臍血多能干細(xì)胞對(duì)阿爾茨海默病患者外周血淋巴細(xì)胞的免疫調(diào)節(jié)作用[D];山東大學(xué);2015年

2 勞滔滔;人和小鼠多能干細(xì)胞的分離和培養(yǎng)[D];浙江大學(xué);2003年

3 張翠平;誘導(dǎo)小鼠胎兒成纖維細(xì)胞為多能干細(xì)胞的共孵育方法研究[D];西南大學(xué);2012年

4 韓升霞;人體細(xì)胞體外重編程為誘導(dǎo)性多能干細(xì)胞關(guān)鍵技術(shù)的研究[D];福建醫(yī)科大學(xué);2013年

5 劉海明;小鼠胚胎成纖維細(xì)胞重編程為多能干細(xì)胞的實(shí)驗(yàn)研究[D];南方醫(yī)科大學(xué);2012年

6 張向前;小鼠誘導(dǎo)性多能干細(xì)胞的建立及其分化研究[D];鄭州大學(xué);2013年

7 唐海燕;人包皮成纖維細(xì)胞體外誘導(dǎo)重編程為多能干細(xì)胞的基礎(chǔ)研究[D];福建醫(yī)科大學(xué);2011年

8 李勇鐵;人誘導(dǎo)性多能干細(xì)胞向表皮樣干細(xì)胞分化的初步研究[D];南昌大學(xué);2011年

9 朱恒濤;誘導(dǎo)性多能干細(xì)胞正常小鼠耳蝸內(nèi)移植的實(shí)驗(yàn)研究[D];南昌大學(xué);2014年

10 張新民;多能干細(xì)胞誘導(dǎo)因子及其家族蛋白的生物信息學(xué)分析[D];內(nèi)蒙古師范大學(xué);2013年

，

本文編號(hào)：1460562